SK Bioscience, the South Korean biotech company based in Incheon, has signed a landmark license agreement with the U.S. Centers for Disease Control and Prevention to develop a new injectable rotavirus vaccine—a breakthrough that could save countless children's lives in the world's poorest countries.
Rotavirus is a brutal disease. It strikes children under five with severe diarrhea and dehydration, but thanks to vaccines, it has nearly vanished from wealthy nations. The grim irony: 99% of rotavirus deaths now occur in low- and middle-income countries, where existing oral vaccines fail to protect adequately. Current vaccines work less than 50% of the time in these regions, undermined by poor sanitation, malnutrition, and limited healthcare access. An injectable alternative could change that equation entirely.
Under the agreement announced on June 9, SK Bioscience will acquire the CDC's injectable inactivated rotavirus vaccine technology and work to optimize its manufacturing process—improving both its protective power and its cost-effectiveness. The CDC has already begun Phase 1 clinical trials with the candidate. SK Bioscience plans to rapidly establish production capacity in Korea and then advance through further clinical trials and regulatory approvals toward commercialization. Research and development costs are being jointly funded by global health foundations, with the Right Foundation having already committed support last year specifically for this vaccine's process development.
Jae-yong Ahn, CEO of SK Bioscience, framed the initiative in human terms: "With the support of the Right Foundation, we are committed to developing innovative vaccines to improve the health of children in low- and middle-income countries and fulfilling our responsibility as a company leading a paradigm shift in global health."
The market opportunity underscores the scale of the need. According to Business Research Insights, the global rotavirus vaccine market is expected to grow from approximately $8.12 billion in 2024 to roughly $13.9 billion by 2033—a sign of rising demand as countries recognize that current tools are insufficient.
What makes this partnership remarkable is its focus on equity. Rotavirus has been controllable for decades in the Global North, yet children in the world's poorest regions continue to suffer and die from a preventable disease. An effective injectable vaccine wouldn't just be a medical advance; it would be a pathway to closing one of global health's most glaring gaps. Injectable vaccines often perform better in challenging environments, where refrigeration may be limited or oral administration is complicated by malnutrition.
SK Bioscience's track record suggests the company can deliver. The firm has demonstrated expertise in vaccine development and manufacturing at scale. The partnership with the CDC—which brings decades of disease surveillance and vaccine research—combines South Korean manufacturing prowess with American scientific rigor.
The work ahead is substantial: process optimization, clinical trials, regulatory navigation, and manufacturing scale-up. But if successful, children in Africa, South Asia, and beyond could gain protection from a disease that still claims young lives unnecessarily. In global health, such partnerships between private enterprise, government institutions, and philanthropic foundations represent the collaborative model that works—combining innovation, funding, and purpose.